Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing treatments for neurodegenerative diseases, has priced an underwritten public offering of 5.25 million shares of common stock and warrants at a combined price of $4 per share. The warrants, … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 … Continue reading →

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and … Continue reading →

Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that … Continue reading →

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward … Continue reading →

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast … Continue reading →

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to … Continue reading →

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the … Continue reading →